INmuneBio MINDFuL (Phase 2)

Back to Drug Development Trials
Drug Development Trials

About the trial

WA only

INmune Bio, Inc is developing XPro™ as a therapy for patients with mild to moderate Alzheimer’s disease who have elevated inflammatory markers in their blood. Researchers believe Alzheimer’s disease may be defined as an inflammatory condition of the brain. It is hoped that by preventing this inflammation pathway the symptoms of Alzheimer’s disease may be improved or stabilised. This drug has been thoroughly tested successfully in oncology patients.

Who can be involved:

  • Male or female, aged 60 – 85 years inclusive, at the time of informed consent
  • Must be diagnosed with mild Alzheimer’s disease
  • Have an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • Weekly/quarterly visits
  • 6 months trial duration
  • Weekly subcutaneous injection (home dosing or self-administration available)
  • Must be able to tolerate MRI scans
  • 33% chance of receiving a placebo

Additional info:

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email:

* Please note that participants in this study may have a chance of being placed on a placebo medication.